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ABSTRACT 
Aim: Faecal incontinence is frequent in the elderly. Little is currently known about the efficacy of 
sacral nerve modulation in the elderly. The present study aimed to assess the impact of age on the 
outcome of sacral nerve modulation and on the surgical revision and explantation rates by comparing 
the results of a large dataset of patients. 
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Method: Prospectively collected data from patients who underwent an implant procedure between 
January 2010 and December 2015 in seven French centres were retrospectively evaluated. Three 
hundred fifty-two patients (321 females, median age 63 years [24-86]) were included. Clinically 
favourable and unfavourable outcomes and surgical revision and explantation rates were compared 
according to the age of the patients. 
Results: A similar outcome was observed when comparing patients <70 years and 70 years (79.2% 
and 76.2% favourable outcome, respectively (p=0.89)). The probability of a successful treatment as a 
function of time was similar for the two age groups (i.e., <70 years and 70 years) (p=0.54). The 
explantation and revision rates were not influenced by age (<70 years vs. 70 years: 17 and 14%, 
respectively, p=0.89, and 42% and 40%, respectively, p=0.89). The probability of explantation as a 
function of time was similar for the two age groups (p=0.82). 
Limitations : Retrospective study, rate of loss at follow-up, and different durations of patient follow-
up. 
Conclusions : Our results suggest that patients 70 years suffering from faecal incontinence benefit 
from sacral nerve modulation with a similar risk as a younger population. 
 
What does this paper add to the literature? 
Patients 70 years suffering from faecal incontinence can expect a similar benefit with a similar risk 
as a younger population when treated with sacral nerve modulation. 
INTRODUCTION 
Faecal incontinence (FI), which is defined as a recurrent chronic loss of ability to control anal 
sphincter and bowel movements resulting in the leakage of faeces, is a frequent condition that 
increases with age [1]. It is experienced by 2-17% of the general population and almost half of 
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nursing home residents [2]. FI has a significant personal impact on the elderly and may be the main 
reason for their institutionalization [3]. It is also a major economic burden on health care systems [4]. 
It is thus of the utmost importance to appropriately manage FI in elderly patients, including dietary 
adjustments, symptomatic treatment of transit disorders, and behavioural therapy, including 
biofeedback [4]. If these conservative approaches fail, sacral nerve modulation (SNM) may be used to 
alleviate the symptoms of patients with FI [5]. SNM involves implanting a device that stimulates the 
sacral roots and that modulates colorectal motility and perception [6]. A successful SNM treatment, 
which is defined as a 50% reduction in FI symptoms, has been reported in 61-100% of trials [7]. 
Although many studies have reported that SNM is effective for treating FI, little is known about the 
influence of age on the outcome of the procedure. Most of these studies included age as a potential 
predictive factor of outcome but failed to establish a correlation between age and SNM results [8-10]. 
The present study aimed to determine whether age, associated with comorbidities, influences the 
efficacy of SNM, especially the success of permanent implantation and the need for surgical revision 
and/or explantation. 
METHODS 
Patients and data collection 
Data prospectively collected from patients who underwent an SNM implant procedure for FI in seven 
French tertiary referral centres (Grenoble, Lyon, Marseille, Nantes, Rennes, Rouen, and Paris) from 
January 2010 to December 2015 were reviewed retrospectively. 
 
Inclusion and exclusion criteria 
Inclusion and exclusion criteria were those usually used to propose SNM. Inclusion criteria were at 
least one episode of FI and/or urgency per week for more than six months, no response to 
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conservative therapies such as anti-diarrheal medications and biofeedback, a successful temporary test 
stimulation, and aged 18 years or over. Exclusion criteria were anatomic limitations preventing 
surgery, existing rectal prolapse, chronic constipation and/or diarrhoea resistant to medical treatment, 
chronic inflammatory bowel disease, active anal abscesses, fistulae, and pregnancy. No upper age 
limit was set on the selection of patients who consulted for FI, had no degenerative disease, did not 
have a high anaesthesia risk, and were not bedridden. 
The present study focused on patients who were implanted at least two years previously in order to 
have a minimally sufficient time lapse between implantation and assessment to properly evaluate the 
effectiveness of SNM. The study protocol was approved by each institution’s human research 
committee (E2018-63) and complied with the ethical guidelines of the 1975 Declaration of Helsinki 
(6th revision, 2008).  
All patients underwent a pre-implantation assessment that included recording their age at the time of 
the SNM procedure, gender, body mass index (BMI), comorbidities (i.e., diabetes, obesity, 
cardiovascular disease including high blood pressure, neurological disease including cerebrovascular 
disease, multiple sclerosis, epilepsy meningioma, psychiatric disorders including depression), type of 
FI (urge and/or passive incontinence), duration of symptoms, and FI severity as assessed by the 
Cleveland Clinical FI score [11]. All patients underwent a preoperative evaluation, including 
anorectal manometry and endoanal ultrasonography, to help determine the main cause of their FI. 
 
Sacral nerve modulation procedure 
A standard two-stage SNM procedure was performed [12]. A percutaneous test was used to assess the 
response of the patients to the treatment, i.e., an improvement of more than 50% in the number of FI 
episodes per week and/or FI days per week. A quadripolar electrode was placed in the right or left S3 
or S4 foramen to assess motor responses, i.e., pelvic floor contraction associated with flexion of the 
ipsilateral hallux. The electrode was then placed in the location that gave the best motor response and 
was connected to an external pulse generator (Interstim Model 3625; Medtronic, Minneapolis, MO, 
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USA) that delivered a continuous stimulation (pulse width 210 sec, frequency 15 Hz). When a 
satisfactory response was obtained, an internal pulse generator (IPG) was subcutaneously implanted 
and was activated by remote control after the procedure, following which the amplitude was adapted 
to the patient’s perception. 
 
Outcome measures 
As in a previous study [13], the primary treatment outcome was defined as favourable if the patient 
reported a therapeutic benefit from SNM, had no new complaints or interventions at the regular 
follow-ups, and did not consider discontinuing the treatment. The treatment outcome was defined as 
unfavourable if the patient was not satisfied with SNM and required an alternative treatment (medical 
treatment excluded) such as stoma formation or if the patient had switched off the IPG or had had it 
surgically removed [13]. Secondary outcomes were defined as improvements in the FI severity scores 
and the rate of surgical revisions or explantations. 
Explantation was defined as the definitive removal of the device. Revision was defined as any 
surgical intervention, except explantation, including the replacement or relocation of any component 
of the device. In the event of multiple indications for revision, loss of efficacy of the device was 
deemed to be the cause solely in the absence of trauma, pain, or battery replacement. Patients were 
considered lost at follow-up if they were not seen in the outpatient unit in the year prior to the data 
collection (December 2017). 
 
Data analysis and statistics 
Patients were stratified into two groups according to their age (<70 years and 70 years). Data were 
reported as means±standard deviations or medians and ranges for continuous variables and 
percentages for categorical variables. For quantitative endpoints, the Mann-Whitney test or Wilcoxon 
test, as appropriate, was used to compare groups. For dichotomous endpoints, Pearson’s chi-square 
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test or Fisher’s exact test, as appropriate, was used. For the treatment outcome, patients who were lost 
at follow-up were not included in the analysis. Explantation-free rates were compared using 
Kaplan–Meier curves and the log-rank test. Survival time was defined as the period between the 
implantation and the discontinuation of the therapy or the choice of another therapy. To provide more 
accurate comparisons of the surgical revision date according to age when the follow-up time was 
different, the rate of revisions per patient-month was calculated. All tests were two-sided. The 
significance level was set at p<0.05. Statistical analyses were performed using Statview version 5.0. 
RESULTS 
Patient characteristics 
Four hundred sixty-nine patients (409 females, median age 63 years [24-86]) underwent a 
percutaneous test for FI during the study period. Of these, 352 (75%) (321 females, median age 63 
years [24-86]) had a positive test result and were permanently implanted. The median age of patients 
with a positive or a negative test result was similar (median age 63 years [24-86] vs. 65 years [25-82], 
p=0.88). 
Of the 352 implanted patients, 253 (72%) and 99 (28%) were respectively aged <70 years (median 59 
years [26-69]) and 70 years (median 74 years [70-86]). Cohort demographics, characteristics, and 
main causes of FI according to age stratification are given in Table 1. There was no significant 
difference between the two age groups in terms of gender, duration of symptoms, type and cause of 
FI, or baseline FI severity scores (Table 1). In terms of comorbidity, obesity was significantly more 
frequent in the younger group (p=0.003) (Table 1) while a cardiovascular history was significantly 
more frequent in the older group (p=0.02) (Table 1). 
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Sacral nerve modulation outcomes 
Of the implanted patients, 47 (13.3%) were lost to follow-up at the time of data cut-off for this article. 
Three hundred and five patients were thus available for the outcome assessment. The mean length of 
follow-up was 3.41.9 years. Two hundred thirty-nine patients (78.4%) reported a favourable 
outcome and 66 (21.6%) reported an unfavourable outcome (Fig. 1). No differences in 
favourable/unfavourable outcomes were observed across age groups (p=0.85) with a similar mean 
length of follow-up (<70 years: 3.3±1.8 years vs. 70 years: 3.2±1.8 years, p=0.64) (Fig. 1). The rate 
of loss to follow-up was also similar between the two groups (p=0.65) (Fig. 1). 
Kaplan-Meier estimates showed that patients in the <70 year group had the same probability of a 
successful treatment as patients in the 70 year group (p=0.54) (Fig. 2). 
Excluding patients lost to follow-up, the overall FI severity score improved significantly over the 
course of the study, with a mean of 14.2±3 at baseline and a mean of 8.4±4.9 at the last follow-up 
visit (p<0.0001). There was no difference in the scores of the two groups of patients (i.e., <70 years 
and 70 years at baseline: 14.2±3 and 14.2±2.9, respectively, p=0.92, and at the last follow-up visit: 
8.1±4.9 and 9±4.9, respectively, p=0.15). There was a significant difference between incontinence 
scores at baseline and at the last follow-up visit for each age group (<70 years: 14.2±3.0 at baseline 
vs. 8.1±4.9 at the last visit, p<0.0001; ≥70 years: 14.2±2.9 at baseline vs. 9.0±4.9 at the last visit, 
p<0.0001). The rates of improvement in the severity scores of the two age groups were not 
significantly different (Fig. 3). 
 
Association between sacral nerve modulation success and predictive factors at baseline 
A number of factors were examined that may predict outcomes (Table 2). Only a neurological disease 
identified as a comorbidity was related to the outcome of SNM. Patients with a neurological disease 
were more likely to experience treatment failure (p=0.003) (Table 2). 
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Adverse events 
A total of 169 surgical revisions were performed in 146 patients. Indications for revision were battery 
depletion in 82 cases (49.7%), loss of efficacy in 19 (11.5%), pain in 17 (10.3%), infection in 15 
(9.1%), dysfunction in 18 (11%), lead migration in 7 (4.2), and other in 7 (4.2%). For 4 patients, the 
indications for revision were unknown. Because the length of follow-up was not identical for all 
patients, the revision rates per patient-month were calculated. These rates did not change according to 
the age of the patients (p=0.75) (Table 3). In addition, indications for revision did not differ 
significantly between the two age groups (Table 3). 
There was no significant difference in the definitive explantation rates, and indications for 
explantation did not differ significantly with age (Table 3). Kaplan-Meier estimates showed that older 
patients had the same risk for explantation as the younger ones (p=0.82) (Fig. 4). The rate of 
reoperations (i.e., revisions and/or explantations) did not differ significantly with obesity (50% in 
obese patients vs. 47.2% in non-obese patients, p=0.78). 
DISCUSSION 
To the best of our knowledge, the present study is the largest to compare the outcomes and revision 
and explanation rates of patients in two age groups who underwent SNM for the treatment of 
refractory FI. Our results showed that 76% of patients aged 70 years who were implanted with a 
permanent device reported a successful SNM outcome, which was similar to the success rate reported 
by the younger group of patients. The revision and explantation rates were not influenced by the age 
of the patients. 
An analysis of the data from a large multicentre cohort of patients suffering from FI and who 
underwent an SNM treatment is particularly important for older patients given that significant 
alterations in the anorectum may occur with aging, including changes in enteric neural structure and 
function [14], which may affect continence and may have a differential impact on neuromodulation 
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treatment modalities. There are relatively few reports of SNM outcomes in older adults , and the 
results are inconclusive. Only one preliminary study of 23 patients aged 65 years led the 
investigators to suggest that older patients perceive a similar benefit as younger patients [15]. 
However, the study was limited to a cohort of only 13 patients 70 years and did not compare them to 
a cohort of younger patients. Of all the studies that assessed age as a predictor of treatment outcome 
[8-10,13], only one reported that age was negatively related to successful outcomes 5 years after 
implantation [13]. Maeda et al. reported that with every 1-year increase in age, the odds of a 
successful outcome decreased by 4.3% [13]. Although we used the same definition of favourable 
outcome as Maeda et al., it might not be possible to compare their results with ours due to different 
population structures. The median age of the population studied by Maeda et al. (60 years [28-88]) 
was slightly lower than ours [13]. Some of the data required to evaluate the impact of age on SNM 
results were missing, including comorbidities that can affect SNM outcomes, particularly in the 
elderly. In the present study, patients with a neurological disease listed as a comorbidity had reduced 
odds of a successful outcome after SNM implantation. However, we cannot exclude the possibility 
that our definition of a favourable outcome may have influenced our results. Younger patients might 
more aggressively seek symptom resolution by other therapies while older patients may give up, keep 
the SNM device turned on, and not ask for alternative treatments. Such influences involving patient 
motivation to continue therapy were not captured in our analysis, but the fact that the FI severity 
scores improved in both the older and younger groups following SNM argues against this hypothesis.  
The second aim of the present study was to evaluate the influence of age on revision and explantation 
rates. We expected that the elderly patients might suffer more complications, especially because of the 
higher prevalence of cardiovascular disease in this group. However, this was not the case. The present 
study, as well as others [15-17], did not find any association between advanced age and definitive 
explantation or revision rates. In addition, an examination of the distribution of the reasons for 
revision or explantation did not reveal any variation with respect to age. Aside from patient-reported 
outcomes, previous studies showed that comorbidities such as obesity can be associated with 
reoperations [17]. However, the present study revealed no influence of obesity on revision or 
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explantation rates. This point is important to mention because of the higher obesity rate in the younger 
group of patients that could bias our results with respect to the influence of age on revisions or 
explantations. 
Our total explantation rate was higher than those previously reported in other large series of patients 
followed on a long-term basis after implantation [10,18,19]. In the present study, 14% of the patients, 
regardless of age, were definitively explanted compared with 3-5% in other studies [10,18,19]. This 
difference could be due to different practices in the surgical centres involved. In the present study, 
most of the explantations were due to a loss of efficacy. In such cases, explantation is not compulsory 
and depends on the patient and/or the surgeon. A standardization of surgical practices may thus be in 
order if we wish to reduce the costs associated with SNM [20]. However, the 40% revision rate 
observed in the present study is consistent with long-term revision rates reported by others [10,13]. 
The limitations of the present study included its retrospective design, which prevented us from 
prospectively analysing data from at least three balanced age groups (i.e., young, middle-aged, 
and old) with a power analysis that takes the rate of loss at follow-up into account. Our 
population was similar to those of previous studies reporting a median age between 55 and 65 
years, with most under 75 years [21]. We could not exclude the possibility that older patients 
might refuse implantation more often than younger patients. As the data came from patients who 
underwent an SNM procedure from 2010 to 2015, the duration of  follow-up differed. Nonetheless, 
the mean duration of the follow-up was similar for the two groups, and the analyses of successful 
outcomes and explantation and revision rates were related to the duration of the follow-up. Although 
the age limit to define the elderly often refers to individuals between 60 and 75 years of age, the Word 
Report on Ageing and Health states that there is no precise age cut-off [22]. Consequently, the choice 
of 70 years as the cut-off in the present study was arbitrarily based on the need to identify a balanced 
sub-group of the most elderly patients. In addition, the present study involved elderly patients who 
were physically and mentally fit. The efficacy of SNM for elderly patients who live in institutions and 
who have a severe motor impairment and/or a mental disability was not investigated. 
A
cc
ep
te
d
 A
rt
ic
le
. 
CONCLUSION 
FI is problematic for many older adults. As the population ages, the need for effective and safe 
management strategies will only increase. It is thus important to conduct ongoing assessments of 
currently available treatments for elderly patients. Our data suggest that older patients exhibit 
significant improvement with a similar reoperation rate as younger patients after neuromodulation for 
FI. Age alone should not be considered as a limiting factor in SNM therapy. 
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Table 1: Cohort demographics, characteristics, and main causes of faecal incontinence according to 
age stratification in 352 patients who underwent definitive SNM battery implantation.  
 
 Aged <70 years  
N=253 
Aged 70 years 
N=99 
P-value 
Demographic characteristics: 
Age (years) 
Female (%) 
Male (%) 
 
BMI (Kg/m
2
)
 
 
Medical comorbidities: 
Mean number per patient 
 
Type of comorbidity* 
   -Diabetes 
   -Cardiovascular disease 
   -Neurolog ic disease 
       -Ep ilepsy 
       -Mult iple sclerosis, spinal cord injury  
       -Stroke 
       -Neuropathy 
       -Others (Parkinson’s , Chiari, sciatica) 
   -Psychiatric disease 
   -Obesity 
   -Other 
59 [24-69] 
230 (90.9) 
23 (9.1) 
N=244 
26.7±5.2 
1.1±1.2 
24 (9.5) 
69 (27.3) 
22 (8.7) 
3 (1.2) 
5 (2) 
7 (2.8) 
2 (0.8) 
5 (2) 
34 (13.4) 
58 (22.9) 
55 (21.7) 
74 [70-86] 
91 (91.9) 
8 (8.1) 
N=95 
24.8±4.1 
1.2±1.1 
10 (10.1) 
40 (40.8) 
10 (10.1) 
0 
0 
6 (6) 
2 (2) 
2 (2) 
11 (11.1) 
10 (10.1) 
28 (28.3) 
-- 
0.93 
0.003 
0.29 
0.99 
0.02 
0.84 
-- 
-- 
0.25 
0.67 
0.99 
0.01 
0.25 
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Faecal incontinence  
Type: 
   -Urge 
   -Passive 
   -Mixed 
 
Duration (months) 
 
 
Main cause*: 
   -Sphincter trauma 
   -Pudendal neuropathy 
   -Neurolog ical d isease (cauda equina 
syndrome, spinal cord disorder, stroke) 
   -Idiopathic  
   -Post-surgery and/or radiotherapy 
   -Other 
 
 
Baseline severity score 
N=244 
98 (40.2) 
75 (30.7) 
71 (29.1) 
N=242 
84.3±88.1 
N=222 
120 (54) 
73 (32.9) 
6 (2.7) 
25 (11.3) 
11 (4.9) 
6 (2.7) 
N=242 
14.2±3 
N=98 
28 (28.6) 
39 (39.8) 
31 (31.6) 
N=90 
92.4±92.6 
N=89 
48 (53.9) 
29 (32.5) 
0 
15 (16.8) 
9 (10.1) 
0 
N=99 
14±3.4 
0.11 
0.60 
0.99 
0.99 
-- 
0.27 
0.15 
-- 
0.77 
Results are expressed as a  nu mber (percentage), a  mean±standard deviation, or a  median (range). The  nu mber o f patients is giv en when different fro m the total 
population. BMI: body mass index. 
*One patient could have more than one comorbidity or cause of faecal incontinence. 
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Table 2: Comparison of background variables, baseline demographics, comorbidities, and faecal 
incontinence characteristics of the favourable and unfavourable outcome groups after permanent 
implantation. Patients lost to follow-up were excluded from this analysis. 
 Favourable outcome 
N=239 
Unfavourable 
outcome 
N=66 
P-value 
Demographic characteristics: 
Age (years) 
Female (%) 
Male (%) 
 
 
BMI (Kg/m
2
)
 
Medical comorbidities: 
Mean number per patient 
 
Type of comorbidity* 
   -Diabetes 
   -Cardiovascular disease 
   -Neurolog ic disease 
   -Psychiatric disease 
   -Obesity 
   -Other 
 
Faecal incontinence: 
Type: 
   -Urge 
   -Passive 
   -Mixed 
63 [26-86] 
223 (93.3) 
16 (6.7) 
N=234 
26.3±5 
1.1±1.1 
22 (14.5) 
70 (46) 
16 (10.5) 
33 (21.7) 
47 (30.9) 
60 (39.5) 
N=244 
98 (40.2) 
75 (30.7) 
71 (29.1) 
63.5 [24-85] 
58 (88) 
8 (12) 
N=65 
26.1±5.5 
1.4±1.4 
8 (17.8) 
26 (57.8) 
13 (28.9) 
9 (20) 
15 (33.3) 
17 (37.8) 
N=66 
22 (33.3) 
27 (40.9) 
17 (25.8) 
0.85 
0.23 
0.60 
0.12 
0.76 
0.22 
0.003 
0.97 
0.90 
0.95 
0.43 
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Duration (months) 
 
 
Main cause*: 
   -Sphincter trauma 
   -Pudendal neuropathy 
   -Neurolog ical d isease 
   -Idiopathic  
   -Post-surgery and/or radiotherapy 
   -Other 
 
 
Baseline severity score 
N=225 
85.8±83.3 
N=213 
120 (56.3) 
63 (29.6) 
3 (1.4) 
28 (13.1) 
13 (6.1) 
6 (2.7) 
N=228 
14.2±2.9 
N=64 
88.1±94.8 
N=64 
34 (53.1) 
26 (40.6) 
2 (3.1) 
7 (10.9) 
7 (10.9) 
2 (3.1) 
N=64 
14.1±3.3 
0.99 
0.76 
0.13 
-- 
0.80 
0.30 
-- 
0.92 
Results are expressed as a  nu mber (percentage), a  mean±standard deviation, or a  median (range). The  nu mber o f patients is giv en when different fro m the total 
population. BMI: body mass index. *One patient could have more than one co morbidity or cause of faecal incontinence. 
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Table 3: Number and reason for revision and explantation procedures according to age in patients 
implanted for faecal incontinence. 
 
 Aged <70 years 
N=253 
Aged 70 years 
N=99 
P-value 
Implant revision: 
Number of patients having a revision 
procedure 
Number of revisions/100 patient-month 
 
Causes of revision procedure*(relative to 
the total number of revisions) 
-Battery depletion 
-Loss of efficacy 
-Pain 
-Infection 
-Dysfunction 
-Lead migration 
-Other 
 
Explantation: 
Number of patients having a definitive 
explantation 
 
Causes of explantation* (relative to the 
total number of explantations) 
-Loss of efficacy 
-Pain 
-Infection 
-Dysfunction 
-Other 
106 (41.9) 
0.003±0.001 
57 (46.7) 
16 (13.1) 
13 (10.7) 
11 (9) 
13 (10.7) 
6 (4.9) 
6 (4.9) 
43 (17) 
21 (48.8) 
7 (16.3) 
14 (32.5) 
5 (11.6) 
5 (11.6) 
40 (40.4) 
0.002±0.009 
25 (58.1) 
3 (7) 
4 (9.3) 
4 (9.3) 
5 (11.7) 
1 (2.3) 
1 (2.3) 
14 (14.1) 
7 (50) 
3 (21.4) 
2 (14.3) 
2 (14.3) 
0 
0.89 
0.75 
0.27 
0.42 
0.99 
0.99 
0.99 
-- 
-- 
0.89 
0.99 
0.97 
0.32 
-- 
-- 
 
Results are expressed as nu mbers (percentages) or means±standard deviations. * One patient could have more than one cause for a revision or explantation 
procedure. 
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Figure 1: Study flowchart. 
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Figure 2: Kaplan-Meier survival analysis for favourable outcomes after sacral nerve modulation 
implantation in the two groups of patients (<70 years vs. 70 years). 
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Figure 3: Comparison of the different rates of improvement in faecal incontinence severity scores 
before and at the last follow-up visit after sacral nerve modulation battery implantation in the two 
groups of patients (<70 years vs. 70 years). 
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Figure 4: Comparative analyses of explantation-free rates in patients treated by sacral nerve 
modulation according to age.  
 
 
